Peptinnovate's exploitation of molecules derived from M.tuberculosis bacteria: The development of a prototype for treating acute inflammatory disease

点击翻译按钮获取中文摘要

Tuberculosis (TB) bacteria are present in about 2 billion people worldwide; they have evolvedover 1000’s of years to remain hidden in the body by producing proteins that modulate thehost's immune system. These proteins have been shown to interact with and reduce the body'snatural inflammatory processes.Peptinnovate’s innovationPeptinnovate’s approach is to unlock the anti-inflammatory activity of these proteins and todevelop new medicines for debilitating diseases such as acute organ failure and chronicobstructive pulmonary disease (COPD) by building on evolution and nature's ingenuity tomodify these proteins to more drug-like molecules.Aims:This project will enable our lead molecule PIN201104 to be synthesised, formulated andtested in preliminary non-clinical studies for acute use via the intravenous route. Alongsidethis we will also carry out in vivo efficacy studies in a range of inflammatory efficacy modelsto widen the therapeutic utility of the molecule.Objectives:? To manufacture active substance in sufficient quantities to perform proposed studies,? To prepare and stability test a formulation to be used in the proposed studies,? To perform preliminary toxicology studies to include testing in a second species,genotoxicity, immunogenicity assays and safety pharmacology studies,? To perform definitive rat and dog DMPK studies,? To demonstrate efficacy in a range of animal models of inflammation to extendPIN201104 range of clinical indications,Main benefits, likely outcomes and impactsThe worldwide market for inflammatory disease treatment is substantial (>$70 billion),however recent safety scares have been attributed to a number of key drugs. Peptinnovate’sparadigm shift in potential treatment options will have a profound impact on the lives ofmillions of patients, reducing the burden on the healthcare providers and helping to build asustainable, UK based pharmaceutical company.